Respondents’ views on the impact of pharmacy provision of the progestogen-only pill and combined oral contraception on sexual and reproductive health outcomes
| Perceived impact on broader sexual and reproductive health outcomes | Improve (n (%)) | Same (n (%)) | Worse (n (%)) | Unsure (n (%)) | Total (n) |
| Impact of POP/COC sale at the pharmacy on | |||||
| Use of effective contraception | 81 (48.2) | 33 (19.6) | 27 (16.1) | 27 (16.1) | 168 |
| Use of bridging (temporary) contraception | 103 (61.3) | 24 (14.3) | 17 (10.1) | 24 (14.3) | 168 |
| Overall use of LARC* | 8 (4.8) | 49 (29.2) | 86 (51.2) | 25 (14.9) | 168 |
| Smear and breast screening | 7 (4.2) | 77 (45.8) | 55 (32.7) | 29 (17.3) | 168 |
| STI screening | 13 (7.7) | 47 (27.8) | 90 (53.3) | 19 (11.2) | 169 |
| Number of unintended pregnancies | 71 (42.3) | 30 (17.9) | 29 (17.3) | 38 (22.6) | 168 |
*LARC methods include intrauterine contraception, implants and injectables.
COC, combined oral contraception;LARC, long-acting reversible contraception;POP, progestogen-only pill; STI, sexually transmitted infection.